Clinical trials: Carcinoma, Breast
Breast Cancer
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
This controlled study is designed to evaluate the relapse-free survival of UFT + TAM compared with CMF + TAM. Patients are randomly assigned to receive either CMF + TAM or UFT + TAM within 6 weeks after surgery.
- Trial name
- NCT00152178
- Testing
- UFT (uracil, tegafur) and tamoxifen, CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
- Where
- Japan
- Volunteers
- 680 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Breast Cancer
TAILORx Tissue Bank
This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.
- Trial name
- NCT02050750
- Where
- 12 sites in Ireland
- Volunteers
- 600 people
- Sponsor
- Cancer Trials Ireland
Metastatic Breastcancer
Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers
Whole-body MRI including diffusion is a booming technique. Numerous studies have demonstrated its interest in metastatic cancers.
- Trial name
- NCT02966574
- Testing
- whole body MRI
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Brugmann University Hospital
Breast Cancer, Prostate Cancer
Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications
The aim of this study is to evaluate and optimize protocols for the isolation and analysis of analytes in urine (cell-free nucleic acids, extracellular vesicles and proteins).
- Conditions
- Breast Cancer, Prostate Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP1 (NCT05453604)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Novosanis NV
Breast Cancer
Psychosocial Outcomes in Online Cancer Support Groups
Purpose: The purpose of this project is to evaluate whether psychosocial outcomes in women with breast cancer differ based on the format of online group support. This objective will be addressed by the following specific aims: 1.
- Trial name
- NCT00382785
- Testing
- moderated support, peer-led
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Christiana Care Health Services
Breast Cancer Female, Mammography Screening
Investigating Barriers for Decision Making in a Danish Breast Cancer Screening Context
The aim is to investigate potential barriers to informed decision making in a breast cancer screening context. This is a necessary step prior to developing and investigating improved information or decision aids in a Danish…
- Conditions
- Breast Cancer Female, Mammography Screening, Decision Making, Information Seeking Behavior
- Trial name
- NCT05444725
- Testing
- Stage of Decision Making, Choice framing, Opportunity Framing
- Where
- Denmark
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Breast Cancers, Breast Cancer Female
Examining the Effectiveness of Multidisciplinary Care Teams in Improving Outcomes for Breast Cancer Patients
To compare clinical outcomes, patient-reported measures (PROMs), and healthcare utilization between standard care with or without an MDCT in a cohort of women treated for breast cancer.
- Conditions
- Breast Cancers, Breast Cancer Female, Breast Cancer Stage I
- Trial name
- MDCT (NCT06856876)
- Testing
- Multidisciplinary Care Team (MDCT) Approach, Standard Breast Cancer Therapy
- Where
- Pakistan
- Volunteers
- 73 people
- Sponsor
- Yousaf Jan
HER-2 Positive Metastatic Breast Cancer
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
This study is for women and men who have previously treated metastatic (has spread to other parts in the body), Her2- positive breast cancer.
- Trial name
- NCT00810017
- Testing
- Etoposide, Trastuzumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medstar Health Research Institute
Triple Negative Breast Cancer, Anthracycline-refractory TNBC
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory…
- Trial name
- INTEGRAL (NCT04095689)
- Testing
- Docetaxel, Pembrolizumab, IL-12 gene therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- The Methodist Hospital Research Institute
Triple Negative Breast Neoplasms
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
This trial is a multicenter, single-arm clinical trial to evaluate the efficacy and safety of UTD1 in combination with capecitabine for the adjuvant treatment of TNBC patients who did not achieve pathologic complete remission…
- Trial name
- NCT06385990
- Testing
- UTD1
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Hunan Cancer Hospital
Febrile Neutropenia
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
This clinical study is a multiple center, registering and real-world conditional research. The breast cancer patients planning for chemotherapy evaluated with medium-high risk of febrile neutropenia (FN) are recruited, receiving…
- Trial name
- NCT03618810
- Testing
- PEGCSF first level prophylactic use, PEGCSF second level prophylactic use
- Volunteers
- 2,000 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Research into treatments for breast cancer relies more and more on an understanding of how the cells of tumor tissue act when they are exposed to a new or different drug.
- Trial name
- NCT01467310
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis
Primary purpose : To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.
- Trial name
- SENOMETRY (NCT02810093)
- Testing
- retrospective medical records analyze
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Strasbourg, France
Breast Neoplasms
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
This is a prospective, single-arm, phase II study of 32 evaluable patients treated with NEOADjuvant Aromatase inhibitor and Pertuzumab/Trastuzumab (NEOADAPT) without chemotherapy for hormone receptor positive (HR+), [i.e.
- Trial name
- NEOADAPT (NCT02689921)
- Testing
- Exemestane, Letrozole, Anastrozole
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Midwestern Regional Medical Center
Breast Neoplasm Female
Evaluation of the Diagnostic Performance of a Bra Prototype to Detect Breast Cancer
Phi-Bra is a prospective and monocentric pilot study to assess the diagnostic capability of an innovative bra prototype to detect breast cancer, compared to the current standard of care: the mammography.
- Trial name
- Phi-Bra (NCT05574816)
- Testing
- Phi-Bra prototype measurements
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Breast Neoplasms
Delphinus SoftVue Prospective Case Collection - ARM 2
The SoftVue™ is a whole breast ultrasound system with an automated scanning curvilinear ring-array transducer that employs UST. It is currently cleared under FDA 510(k) K123209 and K142517 for use as both a B-mode ultrasonic…
- Trial name
- SV PCC ARM2 (NCT02977247)
- Testing
- Non-Interventional, Automated Whole Breast Ultrasound
- Where
- 10 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Metastatic Breast Cancer, Brain Metastases
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions.
- Trial name
- NCT03449238
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Weill Medical College of Cornell University
Cervical Cancer, Ovarian Clear Cell Carcinoma
Asian Multicenter Prospective Study of ctDNA Sequencing
This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types…
- Conditions
- Cervical Cancer, Ovarian Clear Cell Carcinoma, Nasopharyngeal Carcinoma, Ovarian Cancer
- Trial name
- A-TRAIN (NCT05099978)
- Testing
- NGS analysis of ctDNA
- Where
- 19 sites in Japan, Malaysia and 6 more
- Volunteers
- 506 people
- Sponsor
- National Cancer Center, Japan
TNBC, Triple Negative Breast Cancer
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
This study is a single-arm, multicenter, prospective phase II clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for…
- Trial name
- NCT07601178
- Testing
- TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ）
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer.
- Trial name
- NCT06797635
- Testing
- Patritumab deruxtecan, Pembrolizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea and 2 more
- Volunteers
- 372 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.